<DOC>
	<DOCNO>NCT00519714</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , dose-ranging , multi-center study . Following 6-8 week placebo dietary-controlled baseline period , approximately 195 men woman either hypertriglyceridemia mixed hyperlipidemia serum triglyceride ( TG ) &gt; 200 mg/dl ( 2.26 mmol/l ) randomize receive either placebo , 30 mg 1-MNA 90 mg 1-MNA three time daily twelve week . Lipid ancillary exploratory parameter evaluate screening , baseline period , upon randomisation throughout 12-week active treatment period . Additionally , blood sample draw randomisation clinic visit active treatment period sparse sample population pharmacokinetic assessment . All blood sample lipid assessment glucose measurement collect follow 12-hour fast . Safety tolerability assess throughout trial evaluation physical exam , ECGs , routine hematology blood chemistry test , adverse event .</brief_summary>
	<brief_title>A Study Evaluate Lipid Regulating Effects 1-Methylnicotinamide ( 1-MNA )</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients least 18 year age time inform consent ( woman childbearing potential must practice adequate contraception ) Patients mean serum TG &gt; 200 mg/dl ( 2.26 mmol/l ) &lt; 700 mg/dl ( 7.91 mmol/l ) measure 2 sequential visit dietary control baseline period ( Visits 2 3 Visits 3 3a ) low level within 25 % upper level ( high value minus low value ) /higher value &lt; 0.25 ) Patients willing able sign inform consent form follow protocol Patients pregnant nursing Patients evidence hepatic ( ALT AST great 1.5 ULN , bilirubin great 1.5 ULN , cirrhosis ) renal dysfunction ( serum creatinine great 140 Î¼mol/l , nephrotic syndrome ) measure baseline phase Patients uncontrolled diabetes mellitus ( fast glucose level 11 mmol/l HbA1C 10 % ) measure baseline phase Patients hypothyroidism treat stable least 6 month prior study entry Patients uncontrolled hypertension ( systolic blood pressure 160 mm Hg and/or diastolic blood pressure 110 mm Hg ) Patients systolic blood pressure 140 mm Hg AND three follow cardiovascular risk factor : Current cigarette smoker HDLC &lt; 40 mg/dL ( 1.04 mmol/L ) Coronary heart disease male first degree relative &lt; 55 year age Coronary heart disease female first degree relative &lt; 65 year age Male age 45 year old Female age 55 year old Patients know hyperuricemia history gout Patients active peptic ulcer Patients know coronary artery disease , cerebrovascular disease peripheral arterial disease previously require PCI surgical intervention Patients know intolerance allergy niacin Patients consume 10 alcoholic drink per week Patients history drug abuse Patients receive lipid modifying agent within 4 week entry baseline period Patients participate another clinical trial within 30 day entry baseline period Patients consider noncompliant study medication ( &lt; 80 % study medication ) diet placebobaseline phase Patients investigator determines study would appropriate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>